Background: The American Thoracic Society, European Respiratory Society, Japanese
Respiratory Society, and Asociación Latinoamericana del Tórax convened to update clinical …

Background: Two therapeutic options are currently available for patients with mild-to-
moderate idiopathic pulmonary fibrosis (IPF): pirfenidone and nintedanib. To date, there is …

Rationale: FVC has emerged as a standard primary endpoint in clinical trials evaluating
novel therapies for patients with idiopathic pulmonary fibrosis (IPF). However, it has recently …

Summary Background In this retrospective Italian study, which involved all major national
interstitial lung diseases centers, we evaluated the effect of pirfenidone on disease …

Rationale: Nintedanib and pirfenidone slow the progression of idiopathic pulmonary fibrosis
(IPF), but the disease continues to progress. More data are needed on the safety and …

Pirfenidone is an antifibrotic agent that has been evaluated in three multinational phase 3
trials in patients with idiopathic pulmonary fibrosis (IPF). We analysed pooled data from the …

Idiopathic pulmonary fibrosis (IPF), the most common form of fibrosing idiopathic interstitial
pneumonia, is an inexorably progressive disease with a 5-year survival of~ 20%. In the last …

Idiopathic pulmonary fibrosis (IPF) is a progressive disease with poor prognosis. In the last
decades pirfenidone an anti-inflammatory and anti-fibrotic agent has shown benefit in inhibit …

In patients with idiopathic pulmonary fibrosis (IPF), the effects of antifibrotic agents on the
prognosis remain unclear. This study aimed to investigate the impact of antifibrotic treatment …